SG/PUT/MODERNA/80/0.1/20.12.24 | Market Closed - Euronext Paris 07:01:47 25/06/2024 BST | ||
| 0.205 EUR | -4.65% |
|
| 1 month | +65.38% | ||
| 3 months | -68.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 0.205 | -4.65% |
| 24/06/24 | 0.215 | -4.44% |
| 21/06/24 | 0.225 | -4.26% |
| 20/06/24 | 0.235 | -4.08% |
| 19/06/24 | 0.245 | +8.89% |
Real-time Euronext Paris
Last update June 25, 2024 at 07:01 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| U614S | |
| ISIN | DE000SU671V9 |
| Date issued | 22/01/2024 |
| Strike | 80 $ |
| Maturity | 20/12/2024 (179 Days) |
| Parity | 10 : 1 |
| Emission price | 1.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.265 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.01 € |
| Spread % | 4.76% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137
USD
Average target price
145.9
USD
Spread / Average Target
+6.46%
- Stock Market
- Warrants
- U614S Warrant
